| Pair Name | Theaflavin 3,3'-digallate, Trastuzumab | ||
| Phytochemical Name | Theaflavin 3,3'-digallate (PubChem CID: 21146795 ) | ||
| Anticancer drug Name | Trastuzumab (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Theaflavin 3,3'-digallate, Trastuzumab | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Mitosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | MISP | hsa126353 |
| Down-regulation | Expression | PLK1 | hsa5347 | |
| Down-regulation | Expression | SHCBP1 | hsa79801 | |
| In Vitro Model | NCI-N87 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1603 |
| HGC-27 | Gastric carcinoma | Homo sapiens (Human) | CVCL_1279 | |
| MKN45 | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0434 | |
| AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 | |
| KATO II | Down syndrome | Homo sapiens (Human) | CVCL_M882 | |
| Hs 746.T | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0333 | |
| HEK293T | Healthy | Homo sapiens (Human) | CVCL_0063 | |
| SNU-216 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_3946 | |
| Result | These findings suggest an aberrant mitotic HER2-SHCBP1-PLK1 axis underlies trastuzumab sensitivity and offer a new strategy to combat gastric cancer. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021 May 14;12(1):2812. doi: 10.1038/s41467-021-23053-8. | Click |
